An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.
J Am Acad Dermatol
; 84(6): 1652-1666, 2021 06.
Article
in English
| MEDLINE | ID: covidwho-1036592
ABSTRACT
Immune-mediated diseases and immunotherapeutics can negatively affect normal immune functioning and, consequently, vaccine safety and response. The COVID-19 pandemic has incited research aimed at developing a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. As SARS-CoV-2 vaccines are developed and made available, the assessment of anticipated safety and efficacy in patients with immune-mediated dermatologic diseases and requiring immunosuppressive and/or immunomodulatory therapy is particularly important. A review of the literature was conducted by a multidisciplinary committee to provide guidance on the safety and efficacy of SARS-CoV-2 vaccination for dermatologists and other clinicians when prescribing immunotherapeutics. The vaccine platforms being used to develop SARS-CoV-2 vaccines are expected to be safe and potentially effective for dermatology patients on immunotherapeutics. Current guidelines for the vaccination of an immunocompromised host remain appropriate when considering future administration of SARS-CoV-2 vaccines.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Skin Diseases
/
Immunocompromised Host
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
J Am Acad Dermatol
Year:
2021
Document Type:
Article
Affiliation country:
J.jaad.2021.01.047
Similar
MEDLINE
...
LILACS
LIS